Business Context and Reporting Period
This Form 8-K is a current report filed by Ocuphire Pharma, Inc. (trading symbol: OCUP) on February 3, 2021. The filing details the entry into definitive Waiver Agreements with institutional investors, directors, officers, and other holders (collectively, the "Holders") regarding a Securities Purchase Agreement originally executed in June 2020 and amended in November 2020. The agreements finalize terms related to warrant exercises, financing restrictions, and registration rights.
Key Financial Metrics and Capital Structure
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or operating margins. The document focuses exclusively on capital structure adjustments and contractual terms. Key financial terms established include:
- Series A Warrants: Fixed exercise price of $4.4795 per share for an aggregate of 5,665,838 shares.
- Series B Warrants: Fixed aggregate number of 1,708,334 shares (excluding Affiliates who retained initial counts) with an exercise price of $0.0001.
- Liquidity Triggers: "Leak out" restrictions on share sales will remain in effect until the Company raises at least $20,000,000 in gross proceeds from a new equity sale (excluding at-the-market offerings) or until November 19, 2021, whichever is earlier.
Material Changes Versus Prior Period
Effective February 3, 2021, the Company and Holders executed Waiver Agreements that materially altered the terms of the prior Securities Purchase Agreement:
- Warrant Resets: Holders waived future price-based reset provisions. The number of shares and exercise prices for Series A and Series B warrants were permanently fixed.
- Financing Restrictions: Restrictions on filing registration statements and conducting subsequent equity placements were lifted, subject to specific conditions. The Company is now permitted to file a shelf registration statement immediately, provided it includes the shares underlying the Warrants.
- Subsequent Placements: The Company may undertake subsequent equity placements after March 1, 2021. Major Holders retain participation rights (capped at 50% aggregate) until December 31, 2021, though these rights do not apply to at-the-market offerings.
- Registration Rights: Major Holders were granted registration rights requiring the Company to file an initial resale registration statement within 5 trading days of the Effective Date. Affiliates and Other Holders did not receive these rights.
Guidance, Outlook, and Risks
The filing contains no forward-looking financial guidance, revenue projections, or management commentary regarding operational outlook. However, it outlines specific contractual risks and contingencies:
- At-the-Market Offering Restriction: The Company is prohibited from issuing equity securities under an at-the-market offering until on or after April 15, 2021.
- Variable Rate Transactions: Restrictions on variable rate transactions (other than at-the-market offerings) remain in place and were not amended.
- Registration Conditions: The Company retains the right to delay or withdraw registration statements under certain circumstances.
Investor Verification Checklist
- Verify the filing of the initial resale registration statement for Major Holders within 5 trading days of February 3, 2021.
- Monitor the Company's ability to raise the $20,000,000 required to lift "leak out" restrictions on share sales.
- Confirm the timeline for the first permitted at-the-market equity offering (no earlier than April 15, 2021).
- Review the full text of the Waiver Agreement (Exhibit 4.1) for specific indemnification and contribution provisions.
- Track the expiration of Major Holders' participation rights in subsequent placements on December 31, 2021.